http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-894339-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc2f7134efa50484bb359fda73782848 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635 |
| filingDate | 1959-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1962-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-894339-A |
| titleOfInvention | Pharmaceutical preparations containing 6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide |
| abstract | A pharmaceutical preparation comprises 6-chloro - g - sulphamyl - 3,4 - dihydro - 1,2,4 - benzothiadiazine - 1,1 - dioxide (A) or a physiologically tolerable salt thereof and carboethoxy syringate of methyl reserpate (syrosingopine) (B) or a physiologically tolerable salt thereof. Salts of (A) are the alkali metal salts such as sodium and potassium. Salts of (B) are the hydrochloride and sulphate. The preparations are put up in the form of tablet, capsule or pill for oral use. The preparations contain 1 to 20 and preferably 2.0 to 10 and particularly 2.5% of (A) and 0.02 to 0.6 and preferably 0.04 to 0.3 and particularly 0.5% of (B). In oral dosage form, the units comprise 10 to 200 mg. and preferably 20 to 100 mg. and particularly 25 mg. of (A) and 0.2 to 6.0 mg. and preferably 0.4 to 3.0 mg, and especially 0.5 mg. of (B). In one example, (B) is mixed with starch, and (A) is mixed with silica, lactose, sugar and stearic acid powder, the powders are mixed and granulated with aqueous starch paste and 50% alcohol. Specifications 744,290 and 847,064 are referred to. |
| priorityDate | 1958-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.